Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer Cell International is Scopus-indexed (Q1, CiteScore 10.5), WoS SCIE, DOAJ. Published by BioMed Central Ltd.
Checked against the index lists dated .
ISSN 1475-2867Verify ISSN ↗
Publisher: BioMed Central Ltd
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Genetics | 29 / 357 | 92nd | Q1 |
| Oncology | 50 / 428 | 88th | Q1 |
| Cancer Research | 44 / 233 | 81st | Q1 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2001–present, best quartile Q1, CiteScore 10.5.
Cancer Cell International is Q1 in Genetics (rank 29 of 357), Q1 in Oncology (rank 50 of 428) and Q1 in Cancer Research (rank 44 of 233), by CiteScore 2025.
Cancer Cell International is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 10.5, which places it in quartile Q1 at the 92nd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.750, quartile Q1, with an H-index of 100.
The publisher lists an article processing charge of about US$3,190 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Cancer Cell International is published by BioMed Central Ltd. Its ISSN is 1475-2867.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Cancer Cell International has an h-index of 118 and a 2-year mean of 6.3 citations per paper (OpenAlex). Its Scopus CiteScore is 10.5, quartile Q1. On 2-year citations it ranks #36 of 353 Scopus journals in Genetics.
Cancer Cell International published 499 papers in 2025; its busiest recent year was 2021 with 708. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2026), authors are most often from China (49.3%), Iran (8.8%) and South Korea (5.5%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 142 retracted papers are recorded (29 per 1,000 papers). The Problematic Paper Screener flags 10 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.